QA-68

• UNSPSC Description:

  QA-68 (QA-68-ZU81) is an effective PROTAC-class BRD9 degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines[1]. QA-68 can be formed by a target protein ligand (red part) EA-89 (HY-170314), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-I (HY-131318), and a PROTAC linker (black part) Ethyne-C2-Pip-CO-Pip-Boc (HY-170315). E3 ubiquitin ligase and linker can form Lenalidomide-ethyne-C2-Pip-CO-Pip (HY-170319).

• Target Antigen:

  Epigenetic Reader Domain; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;PROTAC

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/qa-68.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCN1C=C(C2=C(C1=O)C=C(C(NC3CCS(CC3)(=O)=O)=O)S2)C4=CC=C(C5=C4)N(C=C5C)CC6CCN(CC6)C(CCC(N7CCN(CC7)C(N8CCN(CC8)CCC#CC9=CC=CC%10=C9CN(C%10=O)C%11CCC(NC%11=O)=O)=O)=O)=O

• Molecular Weight:

  1169.42

• References & Citations:

  [1]Weisberg E, et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 Jul 19;12(7):110.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported